Krishnan Viswanadhan

Chief Strategy and Operations Officer @ Agios. Humbled to be part of biotech innovation.

[Agios @AgiosPharma]

#AgiosNews: We have obtained exclusive global rights to a novel, next‑generation, oral spleen tyrosine kinase (SYK) inhibitor from Oscotec, and will advance this for immune thrombocytopenia (ITP), a rare autoimmune blood disorder.

Read more: https://t.co/k3tQkYvOvy

[Agios @AgiosPharma]

#AgiosNews: We submitted an sNDA to the @US_FDA for U.S. accelerated approval of our first-in-class pyruvate kinase (PK) activator in #SickleCellDisease. We expect acceptance notice in the third quarter of 2026, following FDA’s 60-day review period. Read more: https://t.co/xa61k7jGbG

[Agios @AgiosPharma]

#AgiosNews: @US_FDA approved our first-in-class pyruvate kinase (PK) activator for the treatment of anemia in adults with alpha- or beta-thalassemia – regardless of transfusion status.

Read more here: https://t.co/sP9t49O2dX

[Agios @AgiosPharma]

Krishnan Viswanadhan, Pharm.D, joined us today as our new Chief Corporate Development and Strategy Officer. As a member of our Leadership Team, he will spearhead strategic planning and corporate development initiatives that drive continued growth for our company. With a distinguished career, Krishnan brings extensive experience in global strategy, scientific innovation, and industry leadership, having held senior and executive roles in small and large biopharmaceutical companies.

Read his bio and learn more here: https://t.co/mbGYW37F2M

[Longwood Fund @LongwoodFund]

Congrats to @bebiopharma on the exciting progress to the clinic. It's been an exciting journey since Longwood co-founded the company out of the labs of @ScienceRicker & David Rawlings from
@seattlechildren. Onwards to help patients! @viswanak @leahach @aradovicm @DavidASteinberg

[Be Biopharma @bebiopharma]

The U.S. FDA has granted Orphan Drug Designation to BE-101, a novel engineered B Cell medicine (BCM) being developed for the treatment of Hemophilia B. Full release here: https://t.co/woA8VzUqtK

#BCell #BeBold #BCellMedicines #BCMs

[Be Biopharma @bebiopharma]

Thrilled to announce the clearance of our IND from the FDA for BE-101 for the potential treatment of hemophilia B. We expect to initiate a Phase 1/2 study, BeCoMe-9, in the 2nd half of 2024. Full release here: https://t.co/woA8VzTSEc #BCell #BeBold #BCellMedicines #BCMs

[flora peyvandi @flora_peyvandi]

Be Bio engineers B cells to make the desired protein. Cool method!

[Brian O Mahony @Brianhemophilia]

24. BE Biopharma developing B cell therapy which may mean a continous endogenous protein factory. First human trials in mid 2024
25. Montreal in November has lovely weather- cold but dry and very pleasant 9/9

[Be Biopharma @bebiopharma]

More pioneering research from #ASGCT23! First-of-its-kind preclinical research from a collaboration study with @nih_nhlbi show homing and engraftment of B cells in non-human primates with intact immune systems. #BCcells #ASGCT23 #BeCMs
Full release here: https://t.co/eLeozGNN92

[Be Biopharma @bebiopharma]

The #ASGCT23 Annual Meeting is here! Be Bio is excited to share research on our versatile platform for scalable and effective B cell engineering. Full release here: https://t.co/FHSFuhDhiN

[Be Biopharma @bebiopharma]

We are proud to work alongside the team at Resilience to pioneer engineered B Cell Medicines (BeCM), a new class of cellular therapies.

[Be Biopharma @bebiopharma]

We’re thrilled to be named one of @BosBizJournal’s Best Places to Work in the small company category! This recognition of our commitment to build a truly special place to work and to transform patient lives is rewarding and humbling. https://t.co/3Z0YWs60Ri @bosbizevents #BBJBPTW

[Be Biopharma @bebiopharma]

Today we announced the closing of a $130 million financing round led by ARCH Venture Partners. The funds will support our mission to unleash the power of B cells to drive a new class of cellular medicines.

Read more in our press release: https://t.co/s2jfqg104d

[Be Biopharma @bebiopharma]

The entire Be Bio team is proud to congratulate Dr. Joanne Smith-Farrell, Be Bio CEO, for being named one of the Top 25 Biotech CEOs of 2022 by The Healthcare Technology Report. Learn more about what makes Joanne such an impactful leader in this field: https://t.co/IF4mOVG9G0

[Krishnan Viswanadhan @viswanak]

Nice summary from the frontlines by @AlexHarding7.

[Alex Harding @AlexHarding7]

I spent the past two days taking care of patients at an urgent care clinic in Chelsea, MA. I wrote up some thoughts on what this new COVID wave feels like on the ground. It's very different than previous waves. 🧵

https://t.co/VtY1ehYMj0

[Alex Harding @AlexHarding7]

I spent the past two days taking care of patients at an urgent care clinic in Chelsea, MA. I wrote up some thoughts on what this new COVID wave feels like on the ground. It's very different than previous waves. 🧵

https://t.co/VtY1ehYMj0

[Be Biopharma @bebiopharma]

We’re excited to have Jay Backstrom, M.D., M.P.H., Former Head of R&D at Acceleron, join Be Bio’s Board of Directors! Jay is a seasoned leader bringing over 30 years of experience guiding biotechnology companies through research and development. Read more: https://t.co/7bFQaIdH5a

[Be Biopharma @bebiopharma]

B cells are nature’s medicine factories built to unleash a variety of therapeutic applications. Hear our scientific co-founders, Richard James (@ScienceRicker) & David Rawlings describe the incredible versatility of B cells.
https://t.co/wpFUN76sYs

[Be Biopharma @bebiopharma]

Sean Arlauckas, the first Be Bio team member, reflects back on his first year building out the scientific platform, culture, and team. Thanks for all of the talent, character, and passion you bring day-in and day-out to help patients, Sean. We’re grateful to have you on the team.